Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + Peg-Interferon in Resistant CML
NCT00146913Phase 2Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2004
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a in chronic myeloid leukemia (CML), sponsored by Hospices Civils de Lyon. Primary endpoints: Maintenance of Complete Hematologic Response, Cytogenetic Response and 2 more. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00146913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146913.